The Luo Lingfei research group of Southwest University found that after cerebral infarction, some endogenous meningeal lymphatic vessels rapidly transdifferentiate to form the earliest new blood vessels in the damaged brain area and restore emergency blood supply.
On September 24, 2021, the international authoritative academic journal Developmental Cell published the results of this research online
Developmental Cell After the occurrence of acute cerebral infarction, promoting the rapid production of emergency blood supply in the ischemic penumbra area and even the infarcted area is essential for reducing acute symptoms, reducing injury and mortality, and improving prognosis.
Under the guidance of Professor Luo Lingfei, Dr.
Figure 1: Cerebral vascular regeneration process and its regulatory factors
Figure 1: Cerebral vascular regeneration process and its regulatory factors In summary, the cellular processes of cerebral vascular regeneration (including early emergency regeneration and late full regeneration) demonstrated by Luo Lingfei's group are summarized as follows (Figure 1A): After cerebral infarction or local cerebral vascular network injury, meningeal lymphatic vessels grow in response to the injury quickly In damaged brain parenchymal areas, these endogenous meningeal lymphatic vessels drain tissue fluid to slow down brain edema caused by brain injury; on the other hand, most endogenous lymphatic vessels act as growth tracks and start to guide new cerebral blood vessels to grow along their surface (we It is called the "orbital lymphatic vessel")
This study reveals that emergency neovascularization, which is the first to restore blood supply after severe cerebral infarction, is vital to life-sustaining, is formed by transdifferentiation of endogenous meningeal lymphatic vessels
Related paper information: https://doi.
https://doi.
org/10.
1016/j.
devcel.
2021.
09.
005 https://doi.
org/10.
1016/j.
devcel.
2021.
09.
005
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
![9-[1,1'-biphenyl]-4-yl-3,3'-Bi-9H-carbazole](https://file.echemi.com/fileManage/upload/category/ac71ac0d-8ef6-11ec-89e5-fa163ed06441.png)
